LEXINGTON, Mass.--(BUSINESS WIRE)--Promedior, Inc., a clinical stage biotechnology company developing novel therapeutics for the treatment of fibrosis, today announced that Dr. Olga Pozdynakova of Brigham and Women’s Hospital, Boston, will present additional data from the Company’s ongoing Phase 2 clinical trial of its lead product candidate, PRM-151, for the treatment of myelofibrosis, in a poster presentation at the 20th Congress of the European Hematology Association (EHA) which is being held in Vienna, Austria, from June 11-14, 2015.
Help employers find you! Check out all the jobs and post your resume.
